Eli Lilly Stock News

Eli Lilly and Company (NYSE: LLY) reported revenue of $6.7 billion for the third quarter of 2021, up 18% year-over-year. Reported net income decreased 8% to $1.1 billion, or $1.22 [] The post Eli Lilly and Company (LLY) Earnings: 3Q21 Key Numbers first appeared on AlphaStreet .

RMB Capital Management LLC decreased its position in Eli Lilly and Company (NYSE:LLY) by 8.9% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 6,344 shares of the companys stock after selling 620 shares during the period. RMB Capital Management []

The report comes out as an intelligent and thorough assessment tool as well as a great resource that will help you to secure a position of strength in the global Antidepressants market. It includes Porters Five Forces and PESTLE analysis

Recruitment of 687 patients globally completed in fifteen months, ahead of schedule FRESCO-2 primary objective is to confirm overall clinical benefit seen in the China FRESCO pivotal study 1 , and to support global registrations HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., Dec. 06, 2021 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (" HUTCHMED ") (Nasdaq/AIM: HCM; HKEX: 13) today announces that it has completed patient enrollment of FRESCO-2, a Phase III registration study of fruquintinib, an investigational treatment for the treatment of patients with metastatic colorectal cancer ("CRC") in the U.S., Europe, Japan and Australia. The enrollment goal was reached on December 2, 2021. FRESCO-2 is a randomized, double-blind, placebo-controlled, multicenter trial being conducted in patients with metastatic CRC. The primary endpoint of the study is overall survival ("OS"). This large Phase III trial enrolled patients in over 150 sites in 14 countries. Additional details of the study may be found at clinicaltrials.gov, using identifier NCT04322539 .

Johnson Bixby & Associates LLC acquired a new stake in Eli Lilly and Company (NYSE:LLY) in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 887 shares of the companys stock, valued at approximately $205,000. A number of other institutional investors have also []

Mount Vernon Associates Inc. MD decreased its position in Eli Lilly and Company (NYSE:LLY) by 12.8% in the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 1,154 shares of the companys stock after selling 170 shares during the period. Mount Vernon Associates []

E&G Advisors LP acquired a new position in shares of Eli Lilly and Company (NYSE:LLY) in the third quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor acquired 2,700 shares of the companys stock, valued at approximately $624,000. Other institutional investors and hedge funds also recently made []

Arkadios Wealth Advisors reduced its position in shares of Eli Lilly and Company (NYSE:LLY) by 13.3% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 3,061 shares of the companys stock after selling 470 shares during the period. Arkadios Wealth []

Preclinical data demonstrates sotrovimab retains activity against key Omicron mutations Related Stocks: GSK , LSE:GSK , AZN , LLY , REGN , VIR , SNY ,

Eli Lilly & Co. said Friday that the U.S. Food and Drug Administration has expanded the Emergency Use Authorization (EUA) for its bamlanivimab and etesevimab, taken together, to treat certain high-risk patients that are under the age of 12, even newborns. "With the FDA''s decision to allow use of bamlanivimab with etesevimab in children and infants, Lilly can now offer treatment and prevention options to high-risk individuals of any age," said Daniel Skovronsky, Lilly''s chief scientific and medical officer. Lilly said bamlanivimab and etesevimab taken together retains neutralization activity against the delta variant of the coronavirus that causes COVID-19, and the drug maker is working to understand neutralization activity on the omicron variant. Lilly''s stock, which fell 1.9% in afternoon trading Friday, has rallied 44.0% year to date, while the S&P 500 has gained 19.7%. Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

Strategic Investment Advisors MI boosted its holdings in Eli Lilly and Company (NYSE:LLY) by 7.8% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 3,439 shares of the companys stock after purchasing an additional 249 shares during the period. []

Central Bank & Trust Co. cut its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 4.8% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 2,619 shares of the companys stock after selling 131 shares during the quarter. Central Bank & Trust Co.s []

First National Bank & Trust Co. of Newtown lowered its position in shares of Eli Lilly and Company (NYSE:LLY) by 12.4% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 4,034 shares of the company’s stock after selling 573 shares during the quarter. […]